Affymax, Inc. is a clinical-stage drug development company that is developing a rich pipeline of synthetic peptide-based drugs against clinically-validated targets for the treatment of kidney diseases and cancer. Affymax is a recognized world leader in peptide drug discovery, providing superior product profiles over protein and antibody products.
